Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 3/20 | 0.30 |
| ▸ | CA1 | P00915 | 3/20 | 0.30 |
| ▸ | CA2 | P00918 | 3/20 | 0.30 |
| ▸ | CA7 | P43166 | 3/20 | 0.30 |
| ▸ | CA9 | Q16790 | 3/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378870 | 1.00 | TSHR (0.42) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL19257 | 0.84 | TSHR (0.50) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL444245 | 0.84 | TSHR (0.50) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL19256 | 0.84 | TSHR (0.50) | TSHRHCAR2CA12CA1CA2 | |
| Water SCHEMBL30250355 | 0.81 | TSHR (0.48) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL28883041 | 0.81 | TSHR (0.48) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL31071641 | 0.81 | TSHR (0.48) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL29860029 | 0.81 | TSHR (0.48) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL22690761 | 0.81 | TSHR (0.48) | TSHRHCAR2CA12CA1CA2 | |
| SCHEMBL14074102 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731947-B2 | Deuterated antimicrobial compounds | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-08-22 | — | — | US | disclosed |
| US-20170210769-A1 | TH-302 SOLID FORMS AND METHODS RELATED THERETO | THRESHOLD PHARMACEUTICALS, INC. (US) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731947-B2 | Deuterated antimicrobial compounds | TALDO1, TXNRD1, TXNRD3 | TSHR 3113/4885HCAR2 4305/4885CA12 4535/4885 |
| US-20170210769-A1 | TH-302 SOLID FORMS AND METHODS RELATED THERETO | THPO, TBXAS1, TMSB4X | TSHR 182/4885HCAR2 1957/4885CA12 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.